/Investor DB

Visionary Ventures — Full Portfolio

18 tracked investments · listed companies and verified rows first

Rxsightrxsight.comin𝕏NASDAQ: RXST

RxSight is an ophthalmic medical technology company that developed the Light Adjustable Lens (LAL), an intraocular lens that can be customized after cataract surgery to optimize a patient's vision.

HardwareHealthtechMedical DevicesPasadena, US

Robert H. Grubbs(Director)Daniel M. Schwartz(Director)D. Verne Sharma(Executive Officer, Director)Richard Drinkward(Executive Officer)inRon Kurtz(Chief Medical Officer (former President & CEO))Mark Wilterding(Chief Financial Officer)in

Co-investorsFlying L PartnersForesite CapitalH.I.G. BioHealth PartnersH.I.G. CapitalH.I.G. HealthBridge PartnersLongitude Capital+3 more

Tarsus Pharmaceuticalstarsusrx.comin𝕏NASDAQ: TARS

Tarsus is a biopharmaceutical company focused on developing and delivering medicines that target the root cause of serious diseases with high unmet need, including eye conditions.

BiotechHealthtechMedical Devices

Bobak Azamian(Founder)inJeffrey Farrow(Chief Financial Officer and Chief Strategy Officer)Seshadri Neervannan(Chief Operating Officer)Aziz Mottiwala(Chief Commercial Officer)inDianne Whitfield(Chief Human Resources Officer)inElizabeth Yeu-Lin(Chief Medical Officer)

Co-investorsAPERTURE Venture PartnersFlying L PartnersFrazier Life SciencesVivo CapitalBain Capital Life SciencesRTW Investments L.P.

Iantrekiantrekmed.cominSep 2025 · $42M✓ verified

Iantrek develops micro-interventional ophthalmic surgical technologies focused on enhancing total outflow through the uveoscleral pathway to treat glaucoma.

BiotechHealthtechMedical DevicesElkins Park, US

Tsontcho Ianchulev(Executive Officer, Director)Sean Ianchulev(Founder & Chairman of the Board (CMO))inMichael Haydin(Executive Officer)

BoardJeffry K Weinhuff(Director)Farrell Tyson(Director)Stephen Bloch(Director)in

Co-investorsaMoonCanaan PartnersCivilization Ventures Management, LlcFemHealth VenturesJSD Capital, LLCUS Venture Partners+2 more

ONL Therapeuticsonltherapeutics.cominMar 2023✓ verified

ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.

BiotechHealthtechMedical DevicesAnn Arbor, US

David Zacks(Co-Founder and Chief Scientific Officer)inDavid Esposito(President and Chief Executive Officer)inConstance Chang(Executive Officer)John K Freshley(Executive Officer, Director)inJeffrey A Jamison(Executive Officer)in

BoardAaron Fletcher(Director)in

Co-investorsBios PartnersExSight VenturesInvest MichiganNovartis Venture FundInFocus Capital Partners, LLCJohnson & Johnson Innovation – JJDC+3 more

Orasis Pharmaceuticalsorasis-pharma.comin𝕏Sep 2020 · $30M✓ verified

Orasis is a pharmaceutical company developing drugs for the eye, operating in the ophthalmology and eyecare space.

BiotechHealthtechMedical Devices

Co-investorsArboretum VenturesMaverick Ventures IsraelCatalio Capital ManagementJohnson & Johnson Innovation – JJDCLifeSci Venture PartnersSequoia Capital+1 more

Sydnexissydnexis.comin✓ verified

Sydnexis is a privately held biopharmaceutical company developing SYD-101, a proprietary low-dose atropine formulation in Phase 3 clinical trials to slow the progression of pediatric progressive myopia.

BiotechDigital HealthDel Mar, US

Patrick Johnson(Executive Officer, Promoter)inMary Jaqueline Johnson(Executive Officer)Mary Jacqueline Johnson(Executive Officer)Kevin Johnson(Director)Greg Ostrow(Executive Officer, Director)Kenneth Widder(Executive Officer, Director)

Co-investorsLongitude CapitalRA Capital

Aurion Biotechaurionbiotech.cominApr 2022 · $120M

Aurion Biotech develops regenerative cell therapies for ophthalmology, focused on treating blindness and vision loss from corneal endothelial disease.

BiotechHealthtechMedical DevicesSeattle, US

DAVID ROSTOV(Executive Officer)inGREG KUNST(Executive Officer, Director)PATRICK LALLY(Director)JEANNETTE BANKES(Director)CHRISTINE MCCAULEY(Director)ARNAUD LACOSTE(Executive Officer)

Co-investorsDeerfield Management CompanyFlying L Partners

Iantechiantechmed.com

HealthtechReno, US

Tsontcho Ianchulev(Executive Officer, Director)Charles Warden(Director)Brian Walsh(Executive Officer, Director)Bruce J. Brumfield, Jr.(Director)Glenn Rockman(Director)inJim Mazzo(Director)

Co-investorsGlobal Health Investment CorporationGlobal Health Investment Fund

Mighty Buildingsmightybuildings.comin𝕏Series BDefunct

Mighty Buildings is a construction technology company that uses 3D printing, robotics, and automation to produce prefabricated, sustainable homes.

Construction TechPropTechRoboticsSan Francisco, US

Slava Solonitsyn(Founder)inDmitry Starodubtsev(Founder)inAlexey Dubov(COO)Sam Ruben(Founder)Dmitry Tsymbal(Head of HR)Anton Glance(Director of Manufacturing)

Co-investorsAbies VenturesAlumni VenturesAzure Ventures GroupBay Bridge Ventures ClimateBold Capital PartnersCM Ventures+44 more

Pelagepelagepharma.comin𝕏Oct 2025

Pelage develops regenerative medicines for hair loss based on stem cell biology, with a lead candidate (PP405) that is a topical small-molecule drug designed to reactivate dormant hair follicle stem cells.

BiotechHealthtechLongevityLos Angeles, US

Heather Christofk(Executive Officer)William Lowry(PhD)inChristina Weng(Chief Medical Officer)inNathan Wheeler(Chief Operating Officer)in

BoardCathy Friedman(Director)inDaniel Gil(CEO)

Co-investorsGV (Google Ventures)ARCH Venture PartnersHAWKTAILYK Bioventures

Tear Film Innovationstearfilm.com𝕏
TearClear, Inc.tearclear.comin

BiotechCopley, US

Kevin Hershfield(Executive Officer, Director)in

BoardWilliam Link(Director)Jeffry Weinhuff(Director)Tyler Stowater(Director)Richard Heinick(Director)Steve Pazol(Director)

Co-investorsFlying L PartnersVersant Venture AIV Holdings

Vanavana.org𝕏Nov 2022 · $11.9M

Vana is an open data infrastructure platform that enables individuals to control and manage the data they generate, with the ability to choose how it is used by AI systems.

AI & Machine LearningCrypto & Web3Data & Infrastructure

Art Abal(Founder)Anna Kazlauskas(Founder)

Co-investorsAbstract VenturesAlphaLab CapitalBoxGroupCaladanEarl Grey CapitalFlori Ventures+15 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Centricity VisionCorneagenRe-vanaSurface Pharmaceuticals, Inc.Zeptozone

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.